Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study

No abstract is available for this paper.

• Publication year

  2002

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2002-03-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-001-0737-6PMID 12029551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.

  2009cited by this paper
• Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom

  2009influential reference
• Retinoid X receptor and its partners in the nuclear receptor family.

  2001cited by this paper
• A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy

  2000cited by this paper
• Retinoids in embryonal development.

  2000cited by this paper
• Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology.

  2000cited by this paper
• Molecular study of the sodium-iodide symporter (NIS): a new field in thyroidology.

  2000cited by this paper
• Retinoids in chemoprevention and differentiation therapy.

  2000cited by this paper
• Retinoic Acid Redifferentiation Therapy for Thyroid Cancer

  2000cited by this paper
• Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization.

  1999cited by this paper
• Local activation and inactivation of thyroid hormones: the deiodinase family.

  1999cited by this paper
• Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells

  1999cited by this paper
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

  1999cited by this paper
• Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.

  1999cited by this paper
• Regulation of CD97 protein in thyroid carcinoma.

  1999cited by this paper
• Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma.

  1999cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid Carcinoma

  1998cited by this paper
• Retinoid-induced apoptosis in normal and neoplastic tissues

  1998cited by this paper
• An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues.

  1998cited by this paper
• Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.

  1998cited by this paper
• DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid) increases iodide trapping, inhibits thyroperoxidase and antagonizes the TSH-induced apical iodide efflux in porcine thyroid cells.

  1998cited by this paper
• Redifferentiation therapy with retinoic acid in follicular thyroid cancer.

  1998cited by this paper
• Functional retinoid and thyroid hormone receptors in human thyroid‐carcinoma cell lines and tissues

  1998cited by this paper
• The promoter of the human type I 5'-deiodinase gene--mapping of the transcription start site and identification of a DR+4 thyroid-hormone-responsive element.

  1997cited by this paper
• Carotenoids and Retinoids: A Review of Research, Clinical, and Public Health Applications

  1997cited by this paper
• Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.

  1997cited by this paper
• CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells.

  1997cited by this paper
• Retinoid differentiation therapy in promyelocytic leukemia

  1996cited by this paper
• Retinoids in cancer chemoprevention

  1996cited by this paper
• A History of Vitamin A and Retinoids

  1996cited by this paper
• Molecular mechanisms of retinoid actions in skin

  1996cited by this paper
• Retinoids in lung development

  1996cited by this paper
• The roles of retinoids in vertebrate development.

  1995cited by this paper
• Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines.

  1995cited by this paper
• The RXR heterodimers and orphan receptors.

  1995cited by this paper
• Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling.

  1994cited by this paper
• Vitamin A, differentiation and cancer.

  1994cited by this paper
• Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines.

  1994influential reference
• Retinoids and cancer prevention.

  1992cited by this paper
• Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation.

  1991cited by this paper
• Retinoic acid stimulates the differentiation of PC12 cells that are deficient in cAMP-dependent protein kinase

  1991cited by this paper
• Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro.

  1990influential reference
• Synchronization of the seminiferous epithelium after vitamin A replacement in vitamin A-deficient mice.

  1990cited by this paper
• Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines.

  1983cited by this paper
• Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.

  1980cited by this paper
• Retinoids and cancer prevention

  1979cited by this paper

• Dedifferentiation and Redifferentiation of Follicular-Cell-Derived Thyroid Carcinoma: Mechanisms and Therapeutic Implications

  2025cites this paper
• An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer.

  2025cites this paper
• Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights

  2025cites this paper
• Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis

  2024cites this paper
• Is beta-carotene consumption associated with thyroid hormone levels?

  2023cites this paper
• Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors

  2023cites this paper
• Running Title: Markers for Thyroid Cancer Diagnosis Currently Used and New Molecular Markers for Thyroid Cancer Diagnosis

  2022cites this paper
• Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer

  2022cites this paper
• On tumoural growth and treatment under cellular dedifferentiation

  2022cites this paper
• Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS

  2021cites this paper
• 13-cis-Retinoic Acid: It’s Therapeutic Implications and Adverse Effects

  2021cites this paper
• Next-Generation Molecular Imaging of Thyroid Cancer

  2021cites this paper
• Histopathological prognosis of papillary thyroid carcinoma associated with nutritional status of vitamins A and E

  2021cites this paper
• Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.

  2021cites this paper
• Redifferentiation of radioiodine-refractory thyroid cancers.

  2020cites this paper
• Protein Kinase C Alpha (PKCα) overexpression leads to a better response to retinoid acid therapy through Retinoic Acid Receptor Beta (RARβ) activation in mammary cancer cells

  2020cites this paper
• Oral administration of oyster (Crassostrea gigas) hydrolysates protects against wrinkle formation by regulating the MAPK pathway in UVB-irradiated hairless mice

  2019cites this paper
• Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy

  2019cites this paper
• Low molecular polypeptide from oyster hydrolysate recovers photoaging in SKH-1 hairless mice.

  2019cites this paper
• The effect of radioiodine treatment on the diseased thyroid gland

  2019cites this paper
• 12 Differentiation Therapy in Thyroid Carcinoma

  2018influential citation
• BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer

  2018influential citation
• Novel targeted therapies and immunotherapy for advanced thyroid cancers

  2018cites this paper
• Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

  2018cites this paper
• Active Surveillance for Papillary Thyroid Microcarcinoma: Challenges and Prospects

  2018cites this paper
• Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy

  2017cites this paper
• Thyroid cancer: Redifferentiation — a 'new' option for 131I-negative DTC

  2017cites this paper
• Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

  2017cites this paper
• Role of nuclear receptors in breast cancer stem cells.

  2016cites this paper
• Effects of isotretinoin on the thyroid gland and thyroid function tests in acne patients: A preliminary study

  2016cites this paper
• Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer

  2016cites this paper
• Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma

  2016cites this paper
• Radionuclide Therapy of Thyroid Tumors

  2016cites this paper
• MicroRNAs in the thyroid.

  2016cites this paper
• Targeting a Trigger: Platelet Derived Growth Factor Receptor Alpha in the Nodal Metastasis of Papillary Thyroid Cancer

  2016cites this paper
• Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome

  2016cites this paper
• The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation

  2016cites this paper
• Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

  2016cites this paper
• Radioiodine-Refractory Thyroid Cancer: Restoring Response to Radioiodine Therapy

  2016cites this paper
• Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.

  2015cites this paper
• 111In-pentetreotide scintigraphy and 18F FDG PET-CT in differentiated thyroid carcinoma metastases with negative whole body radioiodine scan.

  2015cites this paper
• PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.

  2015cites this paper
• Retinoic acid receptors: from molecular mechanisms to cancer therapy.

  2015cites this paper
• New Strategies for Combined Radioiodine Therapy in Refractory Thyroid Cancer

  2015cites this paper
• The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.

  2014cites this paper
• Actualités dans la prise en charge des cancers thyroïdiens de souche vésiculaire

  2014cites this paper
• Differentiated thyroid cancer—personalized therapies to prevent overtreatment

  2014cites this paper
• Nuclear Receptor Expression in Human Differentiated Thyroid Tumors

  2014cites this paper
• Guidelines for the management of thyroid cancer

  2014cites this paper
• The Na+/I− Symporter (NIS) and Thyroid Hormone Biosynthesis

  2014cites this paper
• Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.

  2014cites this paper
• Radiovirotherapy for the Treatment of Cancer

  2014cites this paper
• [What's new in follicular thyroid cancer management in 2014?].

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Anomalies moléculaires de la voie MAPK et cancer papillaire de la thyroïde : étude de deux phosphatases spécifiques de ERK, DUSP5 et DUSP6

  2014cites this paper
• Thyroid and Parathyroid Tumors

  2013cites this paper
• Kopf-Hals-Tumoren

  2013cites this paper
• Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

  2013cites this paper
• Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid

  2013cites this paper
• Moving toward a better understanding of radioiodine action

  2013cites this paper
• Radiofrequency induction on sodium/iodide symporter expression of thyroid cancer

  2013cites this paper
• Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome.

  2012cites this paper
• Redifferentiation Therapy in Thyroid Cancer

  2012cites this paper
• Differentiation Therapy in Thyroid Carcinoma

  2012influential citation
• New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review

  2012cites this paper
• New treatment modalities in advanced thyroid cancer.

  2012cites this paper
• Nicht-medulläre Schilddrüsenkarzinome – Neue Strategien und aktuelle medikamentöse Therapiekonzepte

  2012cites this paper
• Targeted Therapy of Thyroid Cancer

  2012cites this paper
• Effects of Rosiglitazone on Radioiodine Negative and Progressive Differentiated Thyroid Carcinoma as Assessed by 124I PET/CT Imaging

  2012cites this paper
• Anticancer activity of 9-cis-retinoic acid encapsulated in PEG-coated PLGA-nanoparticles

  2011cites this paper
• Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence

  2011cites this paper
• Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

  2011cites this paper
• Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma

  2011cites this paper
• Increased uptake of [ 23 I ] meta-iodobenzylguanidine , [ 18 F ] fluorodopamine , and [ 3 H ] norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors

  2011cites this paper
• Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma.

  2011cites this paper
• AUF1 and HuR: possible implications of mRNA stability in thyroid function and disorders

  2011cites this paper
• iodobenzylguanidine, [F]fluorodopamine, and [H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors

  2011cites this paper
• Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

  2011influential citation
• Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience

  2011cites this paper
• Targeted Radionuclide Therapy

  2011cites this paper
• Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma.

  2011cites this paper
• Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

  2011cites this paper
• Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

  2011cites this paper
• Update on recent developments in the therapy of differentiated thyroid cancer.

  2010cites this paper
• Terapia medico-nucleare

  2010cites this paper
• Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma.

  2010cites this paper
• Nuklearmedizinische Therapie und Nachsorge des differenzierten Schilddrüsenkarzinoms: Status quo

  2010cites this paper
• Standard and emerging therapies for metastatic differentiated thyroid cancer.

  2010cites this paper
• Charakterisierung der Effekte verschiedener differenzierungssteigernder Substanzen auf Radioiodaufnahme, Thymidininkorporation, NIS- und Pendrin- Expression und Apoptose in der cancerogenen Schilddrüsenzelllinie FTC-238

  2010cites this paper
• Terapia medico-nucleare 16

  2010cites this paper
• Neue molekulare Therapien bei fortgeschrittenem di ff erenziertem Schilddr ü senkarzinom New Molecular Targeted Therapies in Advanced Di ff erentiated Thyroid Cancer

  2010cites this paper
• Usporedba različitih doza joda 131 u ablaciji ostatnog tkiva štitnjače zbog papilarnog karcinoma, te uloga rekombinantnog humanog tireotropina (rhTSH) kod ablacije

  2010cites this paper
• Combined effects of all trans retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells

  2010cites this paper
• Neue Therapieformen beim Schilddrüsenkarzinom

  2010cites this paper
• Viral Introduction of Receptors for Targeted Radiotherapy

  2010cites this paper
• The biology of the sodium iodide symporter and its potential for targeted gene delivery.

  2010cites this paper
• Differentiated thyroid carcinoma : nuclear medicine studies

  2009cites this paper
• Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid.

  2009cites this paper
• 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

  2009cites this paper
• Application of radioisotope imaging and therapy in patients with breast carcinomas that express the sodium iodide symporter gene

  2009cites this paper